In celebration of the 50th episode of our Diagnosing Health Care podcast, we’re looking at how the past 50 years of health law will impact health care in the next 50 years.
On this episode, Epstein Becker Green attorneys...more
This Diagnosing Health Care episode dives into the prospects of coverage expansion following the 2020 elections and also examines three major health care policy reform issues that have bipartisan support and could see...more
10/22/2020
/ Billing ,
Coronavirus/COVID-19 ,
Drug Pricing ,
Health Care Providers ,
Health Insurance ,
Healthcare Reform ,
Legislative Agendas ,
Medicare ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Presidential Elections ,
Relief Measures ,
Surprise Medical Bills
Based on their extensive experience advising health care industry clients, Epstein Becker Green attorneys and strategic advisors from EBG Advisors are predicting the “hot” health care sectors for investment, growth, and...more
1/9/2020
/ Artificial Intelligence ,
Biologics ,
Clinical Trials ,
Electronic Medical Records ,
Health Care Providers ,
Health Information Technologies ,
Health Insurance ,
Healthcare Facilities ,
Hospitals ,
Investment Opportunities ,
Long Term Care Facilities ,
Medical Devices ,
Medicare Advantage ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Private Equity ,
Research and Development ,
Telehealth ,
Telemedicine
On March 31, 2014, in U.S. ex rel. Nathan v. Takeda Pharmaceuticals North America, the Supreme Court of the United States declined to review a decision by the U.S. Court of Appeals for the Fourth Circuit upholding a district...more
6/7/2014
/ Certiorari ,
Dismissals ,
False Claims Act (FCA) ,
Healthcare Fraud ,
Medicare ,
Off-Label Use ,
Pharmaceutical Industry ,
Pleading Standards ,
Popular ,
Qui Tam ,
Rule 9(b) ,
SCOTUS ,
Split of Authority ,
Takeda Pharmaceuticals ,
Whistleblowers